Aligos Therapeutics (ALGS) Total Current Liabilities (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Total Current Liabilities for 8 consecutive years, with $28.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 39.86% year-over-year to $28.3 million; the trailing twelve-month figure through Jun 2026 stood at $28.3 million (up 39.86% YoY), and the FY2025 full-year result was $21.2 million, down 2.32% from the prior year.
• Total Current Liabilities climbed to $28.3 million in Q2 2026 per ALGS's latest filing, from $23.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $41.4 million in Q1 2022 and bottomed at $18.9 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $25.4 million across 5 years, with a median of $23.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities jumped 63.91% in 2022, then plunged 32.76% in 2024.
• Over 5 years, Total Current Liabilities stood at $33.1 million in 2022, then decreased by 27.84% to $23.9 million in 2023, then slipped by 9.07% to $21.7 million in 2024, then retreated by 2.32% to $21.2 million in 2025, then soared by 33.49% to $28.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $28.3 million, $23.3 million, and $21.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.